SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the
Goldman Sachs 40th Annual Health Care Conference on
Wednesday, June 12, 2019 at 10:00 am PT. Gerrit Klaerner, Tricida’s
Founder, President and Chief Executive Officer, will provide a company
overview, business update and progress on the company’s key initiatives.
A live webcast of the presentation will be accessible on the Tricida
website at IR.Tricida.com.
An archive of the webcast will be available for 90 days following the
presentation.
About Tricida
Tricida, Inc. is a pharmaceutical company focused on the development and
commercialization of its drug candidate, veverimer (TRC101), a
non-absorbed, orally-administered polymer designed to treat metabolic
acidosis in patients with chronic kidney disease (CKD). Metabolic
acidosis is a condition commonly caused by CKD that is believed to
accelerate the progression of kidney deterioration. It is estimated to
pose a health risk to approximately three million patients with CKD in
the United States. Tricida has successfully completed all of the
clinical trials that it planned to complete prior to submission of an
NDA to the U.S. Food and Drug Administration (FDA). Tricida plans to
submit an NDA in the second half of 2019, seeking approval of veverimer
through the FDA’s Accelerated Approval Program.
For more information about Tricida, please visit www.Tricida.com.
Cautionary Note on Forward-Looking Statements
This press release includes forward-looking statements, including for
example, statements about our ability to submit an NDA for veverimer
under the FDA’s Accelerated Approval Program. Forward‐looking statements
involve known and unknown risks, uncertainties, assumptions and other
factors that may cause our actual results, performance or achievements
to be materially different from any future results, performance or
achievements expressed or implied by the forward‐looking
statements. These risks and uncertainties include, among others, timing
and results of clinical trials and other studies; that many drug
candidates that have completed Phase 3 trials do not become approved
drugs on a timely or cost effective basis or at all; there can be no
assurance that the FDA would approve an NDA under the Accelerated
Approval Program, or at all, and even if approval for a drug is
obtained, there can be no assurance that it will be adopted in the
market or accepted as a benefit to patients and healthcare providers;
possible safety and efficacy concerns; and that we completely rely on
third-party suppliers to manufacture our clinical drug supply. The
forward-looking statements contained in this press release reflect
Tricida’s current views with respect to future events, and Tricida does
not undertake and specifically disclaims any obligation to update any
forward-looking statements.
Contacts
Jackie Cossmon, IRC
Tricida, Inc.
Vice President of Investor
Relations and Communications
IR@Tricida.com